AR052900A1 - Derivados de tiazol, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos para el tratamiento de enfermedades mediadas por ece-1 - Google Patents
Derivados de tiazol, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos para el tratamiento de enfermedades mediadas por ece-1Info
- Publication number
- AR052900A1 AR052900A1 ARP060100432A ARP060100432A AR052900A1 AR 052900 A1 AR052900 A1 AR 052900A1 AR P060100432 A ARP060100432 A AR P060100432A AR P060100432 A ARP060100432 A AR P060100432A AR 052900 A1 AR052900 A1 AR 052900A1
- Authority
- AR
- Argentina
- Prior art keywords
- 4alkyl
- alkylene
- optionally substituted
- halogen
- alkyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102100029112 Endothelin-converting enzyme 1 Human genes 0.000 title 1
- 108030001679 Endothelin-converting enzyme 1 Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 52
- 125000002947 alkylene group Chemical group 0.000 abstract 27
- 229910052736 halogen Inorganic materials 0.000 abstract 22
- 150000002367 halogens Chemical group 0.000 abstract 22
- 150000001875 compounds Chemical class 0.000 abstract 13
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 10
- 125000001072 heteroaryl group Chemical group 0.000 abstract 10
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- -1 C1-6 alkoxyC1 -6 Chemical group 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000003107 substituted aryl group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 abstract 2
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 abstract 1
- 101150020251 NR13 gene Proteins 0.000 abstract 1
- 206010061876 Obstruction Diseases 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- CPGRMGOILBSUQC-UHFFFAOYSA-N phosphoryl azide Chemical compound [N-]=[N+]=NP(=O)(N=[N+]=[N-])N=[N+]=[N-] CPGRMGOILBSUQC-UHFFFAOYSA-N 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un proceso para su preparacion; composiciones farmacéuticas que los contienen; y su uso en terapia de la obstruccion pulmonar cronica. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1), donde: R1 es arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido; R2 es ciano, CF3, halogeno o XR7; R3 es arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido o cicloalquilo C3-7 [opcionalmente sustituido con halogeno o alquilo C1-4]; A es NR4 o CR5R6; R4, R5 y R6 representan en forma independiente entre sí hidrogeno o alquilo C1-4 o cicloalquilo C3-7 [opcionalmente sustituido con halogeno o alquilo C1-4]; X es un enlace simple, alquileno C1-6 [opcionalmente sustituido con halogeno], alquenileno C2-6 [opcionalmente sustituido con halogeno], alquinileno C2-6 [opcionalmente sustituido con halogeno], S(O)n, NR8C(O), C(O)NR9, NR10, C(O), OC(O), C(O)O, OalquilenoC1-4, S(O) nalquilenoC1-4, NR11C(O)alquilenoC1-4, C(O)NR12alquilenoC1-4, NR13alquilenoC1-4, C(O)alquilenoC1-4, OC(O)alquilenoC1-4, C(O) OalquilenoC1-4, alquilenoC1-4O, alquilenoC1-4S(O)n, alquilenoC1-4NR14C(O), alquilenoC1-4C(O)NR15, alquilenoC1-4NR16, alquilenoC1-4C(O), alquilenoC1-4OC(O), alquilenoC1-4OalquilenoC1-4, alquilenoC1-4S(O)nalquilenoC1-4, alquilenoC1-4NR17C(O) alquilenoC1-4, alquilenoC1-4C(O)NR18alquilenoC1-4, alquilenoC1-4NR19alquilenoC1-4, alquilenoC1-4C(O)alquilenoC1-4, alquilenoC1-4OC(O)alquilenoC1-4 o alquilenoC1-4C(O)OalquilenoC1-4; R7 es hidrogeno, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, cicloalquilo C3-7 [opcionalmente sustituido con halogeno o alquilo C1-4], un anillo heterociclilo alifálico de entre 4 y 8 miembros [opcionalmente sustituido con halogeno o alquilo C1-4], OR20, NR21R22, C(O)R23, CO2R24, OC(O)R25, C(O)NR26R27, S(O)nR28, SO2NR29R30, NR32C(O)R33, NR34C(O)OR35, fenoxi [opcionalmente sustituido con halogeno, ciano CF3 o alquilo C1-4] o heteroariloxi [opcionalmente sustituido con halogeno, ciano, CF3 o alquilo C1-4]; R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R32, R33, R34 y R35 son, en forma independiente, hidrogeno alquilo C1-6 [opcionalmente sustituido con halogeno]; las porciones arilo y heteroarilo están opcionalmente sustituidas en forma independiente con uno o más de halogeno, ciano, nitro, OC(O)NR36R37, NR38R39, NR40C(O)R41, NR42C(O)NR43R44, S(O)2NR45R46, NR47S(O)2R48, C(O)NR49R50, CO2R51, NR52CO2R53, S(O)nR54, OS(O)2R55, alquilo C1-6 [opcionalmente monosustituido con S(O)2R56 , C(O) NR57R58 o NR31R62], C(O)R59, NR60C(O)R61, alquenileno C2-6 [opcionalmente sustituido con fenilo o heteroarilo], alquinileno C2-6 [opcionalmente sustituido con fenilo o heteroarilo], cicloalquilo C3-7, haloalquilo C1-6, alcoxiC1-6alquilenoC1-6, alcoxi C1-6, haloalcoxi C1-6, fenilo, fenil-alquilenoC1-4, fenoxi, feniltio, fenilS(O), fenilS(O)2, fenil-alcoxiC1-4, heteroarilo, heteroaril- alquiloC1-4, heteroariloxi, heteroaril-alcoxiC1-4 o un anillo heterocíclico alifático de entre 4 y 8 miembros [opcionalmente sustituido con halogeno o alquilo C1-4]; donde cualquiera de las porciones fenilo y heteroarilo inmediatamente precedentes están opcionalmente sustituidas con halogeno, nitro, NH2, NHalquiloC1-4, N(alquil C1-4)2, SalquiloC1-4, S(O)alquiloC1-4, S(O)2alquiloC1-4, S(O)2NH2, S(O)2NHalquiloC1-4, S(O)2N(alquilo C1-4)2, ciano, alquilo C1-4, alcoxi C1-4, C(O)NH2, C(O)NHalquiloC1-4, C(O)N(alquil C1-4)2, CO2H, CO2alquiloC1-4, NHC(O)alquiloC1-4, NHS(O)2alquiloC1-4, C(O)alquiloC1-4, CF3 o OCF3; R31, R36, R37, R38, R39, R40, R41, R42, R44, R45, R46, R47, R49, R50, R51, R52, R53, R57, R58, R59, R60, R61 y R62 son, en forma independiente, hidrogeno alquilo C1-6 [opcionalmente sustituido con halogeno, cicloalquilo C3-6 o fenilo {opcionalmente sustituido con halogeno o alquilo C1-4}]; CH2alqueniloC2-6, fenilo [a su vez opcionalmente sustituido con halogeno, nitro, NH2, NHalquiloC1-4, N(alquil C1-4)2, SalquiloC1-4, S(O)alquiloC1-4, S(O)2alquiloC1-4, S(O)2NH2, S(O) 2NHalquiloC1-4, S(O)2N(alquil C1-4)2, ciano, alquilo C1-4, alcoxi C1-4, C(O)NH2, C(O)NHalquiloC1-4, C(O)N(alquil C1-4)2, CO2H, CO2alquiloC1-4, NHC(O)alquiloC1-4, NHS(O)2alquiloC1-4, C(O)alquiloC1-4, CF3 o OCF3] o heteroarilo [a su vez opcionalmente sustituido con halogeno, nitro, NH2, NHalquiloC1-4, N(alquil C1-4)2, SalquiloC1-4, S(O)alquiloC1-4, S(O)2alquiloC1-4, S(O)2NH2, S(O) 2NHalquiloC1-4, S(O)2N(alquil C1-4)2, ciano, alquilo C1-4, alcoxi C1-4, C(O)NH2, C(O)NHalquiloC1-4, C(O)N(alquil C1-4)2, CO2H, CO2alquiloC1-4, NHC(O)alquiloC1-4, NHS(O)2alquiloC1-4, C(O)alquiloC1-4, CF3 o OCF3]; R48, R54, R55 y R56 son, en forma independiente, alquilo C1-6 [ opcionalmente sustituido con halogeno, cicloalquilo C3-6 o fenilo {opcionalmente sustituido con halogeno o alquilo C1-4}], CH2alqueniloC2-6, fenilo [a su vez opcionalmente sustituido con halogeno, nitro, NH2, NHalquiloC1-4, N(alquil C1-4)2, Salquilo C1-4, S(O)alquiloC1-4, S(O)2alquiloC1-4, S(O)2NH2, S(O)2NHalquiloC1-4, S(O)2N(alquil C1-4)2, ciano, alquilo C1-4, alcoxi C1-4, C(O)NH2, C(O)NHalquiloC1-4, C(O)N(alquil C1-4)2, CO2H, CO2alquiloC1-4, NHC(O)alquiloC1-4, NHS(O)2alquiloC1-4, C(O)alquiloC1-4, CF3 o OCF3] o heteroarilo [a su vez opcionalmente sustituido con halogeno, nitro, NH2, NHalquiloC1-4, N(alquil C1-4)2, SalquiloC1-4, S(O)alquiloC1-4, S(O)2alquiloC1-4, S(O)2NH2, S(O)2NHalquiloC1-4, S(O)2N(alquil C1-4)2, ciano, alquilo C1-4, alcoxi C1-4, C(O)NH2, C(O)NHalquiloC1-4, C(O)N(alquil C1-4)2, CO2H, CO2alquiloC1-4, NHC(O)alquiloC1-4, NHS(O)2alquiloC1-4, C(O)alquiloC1-4, CF3 o OCF3]; y n es 0,1 o 2; o una sal aceptable para uso farmacéutico del mismo. Reivindicacion 12: Un proceso para la preparacion de un compuesto de formula (1) de acuerdo con la reivindicacion 1, o una sal aceptable para uso farmacéutico del mismo, caracterizado porque comprende: a) cuando A es CRR5R6 acoplar un compuesto de formula (2), con un compuesto de formula (3); b) cuando A es NH hacer reaccionar un compuesto de formula (4), con un compuesto de formula (3) segun se define en a) en presencia de una azida de fosforilo; o c) cuando A es NH hacer reaccionar un compuesto de formula (5), con un compuesto de formula (3) segun se define en a); o d) cuando A es NR4 hacer reaccionar un compuesto de formula (6), con un compuesto de formula (7), y opcionalmente luego de a), b), c) o d) llevar a cabo uno o más de los siguientes pasos: convertir el compuesto a otro compuesto de la presente; o formar una sal aceptable para uso farmacéutico del compuesto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0500336 | 2005-02-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR052900A1 true AR052900A1 (es) | 2007-04-11 |
Family
ID=36793310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060100432A AR052900A1 (es) | 2005-02-11 | 2006-02-07 | Derivados de tiazol, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos para el tratamiento de enfermedades mediadas por ece-1 |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR052900A1 (es) |
| TW (1) | TW200639156A (es) |
| UY (1) | UY29370A1 (es) |
| WO (1) | WO2006085815A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014078322A1 (en) * | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| PE20221627A1 (es) | 2015-02-16 | 2022-10-19 | Univ Queensland | Sulfonilureas y compuestos relacionados y uso de estos |
| BR112019024831A2 (pt) | 2017-05-24 | 2020-06-09 | The University Of Queensland | composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3 |
| PT3661925T (pt) | 2017-07-07 | 2022-01-31 | Inflazome Ltd | Novos compostos de sulfonamida-carboxamida |
| EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| EP3668840A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| WO2019034693A1 (en) * | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| WO2019034696A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| WO2019034692A1 (en) * | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| BR112020002948A2 (pt) * | 2017-08-15 | 2020-08-11 | Inflazome Limited | novos compostos de sulfonamida-carboxamida |
| JP2020531453A (ja) | 2017-08-15 | 2020-11-05 | インフレイゾーム リミテッド | Ｎｌｒｐ３阻害剤としてのスルホニルウレアおよびスルホニルチオウレア |
| US12221434B2 (en) | 2017-11-09 | 2025-02-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| JP2021502364A (ja) | 2017-11-09 | 2021-01-28 | インフレイゾーム リミテッド | 新規なスルホンアミドカルボキサミド化合物 |
| WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| US20230011652A1 (en) * | 2018-10-24 | 2023-01-12 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| SG10201909596RA (en) * | 2019-10-14 | 2021-05-28 | Esco Aster Pte Ltd | Synthesis of Tyrosine Kinase Inhibitors |
| WO2025163462A1 (ko) * | 2024-02-02 | 2025-08-07 | 삼진제약주식회사 | 헤테로고리를 갖는 mrgprx2((mas-related g-protein coupled receptor member x2) 길항제 유도체와 이의 용도 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997030978A1 (en) * | 1996-02-26 | 1997-08-28 | Sumitomo Pharmaceuticals Company, Limited | Sulfonylureidopyrazole derivatives |
| WO2003039451A2 (en) * | 2001-11-08 | 2003-05-15 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole pyridazinones as adenosine antagonists |
| CL2004000545A1 (es) * | 2003-03-18 | 2005-01-28 | Pharmacia Corp Sa Organizada B | Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul |
-
2006
- 2006-02-07 WO PCT/SE2006/000168 patent/WO2006085815A1/en not_active Ceased
- 2006-02-07 AR ARP060100432A patent/AR052900A1/es not_active Application Discontinuation
- 2006-02-10 TW TW095104480A patent/TW200639156A/zh unknown
- 2006-02-10 UY UY29370A patent/UY29370A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| UY29370A1 (es) | 2006-10-02 |
| TW200639156A (en) | 2006-11-16 |
| WO2006085815A1 (en) | 2006-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR052900A1 (es) | Derivados de tiazol, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos para el tratamiento de enfermedades mediadas por ece-1 | |
| AR053405A1 (es) | Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias | |
| AR045761A1 (es) | Derivados de 2-piridona como inhibidores de elastasa de neutrofilos | |
| AR045389A1 (es) | Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido | |
| AR059338A1 (es) | N-fenilbenzotriazolilo como inhibidores de c-kit | |
| AR046083A1 (es) | Derivados de 2 piridona como inhibidores de la elastasa de neutrofilos | |
| AR059458A1 (es) | Arildihidroisoquinolinonas sustituidas con azaciclilo, procedimiento para su preparacion y su uso como medicamentos | |
| AR074648A1 (es) | Derivados de isoxazolina que poseen un anillo de cuatro miembros como grupo terminal, intermediarios de sintesis, composiciones biocidas que los contienen y metodos para combatir y controlar dichas plagas | |
| AR066972A1 (es) | Derivados azapeptidicos | |
| AR064889A1 (es) | Derivados de piridopirimidinas, un metodo para su preparacion, una composicion y un producto farmaceutico que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por pde-4 | |
| PE20080318A1 (es) | Derivados de diceto-piperazina y piperidina como agentes antivirales | |
| PE20170127A1 (es) | Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas | |
| AR058546A1 (es) | Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1 | |
| AR077143A1 (es) | Compuestos insecticidas | |
| AR069364A1 (es) | Derivados heterociclicos que modulan la miosina del musculo liso y/o la miosina no muscular y composiciones farmaceuticas que los contienen | |
| AR056199A1 (es) | Derivados de 8-oxoadenina 9-sustituida | |
| AR067051A1 (es) | Indazoles sustituidos, su preparacion y su utilizacion terapeutica | |
| AR083953A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| ES2570127T3 (es) | Compuestos y composiciones como inhibidores de la proteína quinasa | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| PE20070751A1 (es) | Derivados de isoxazolidina como inhibidores de la interaccion de proteinas bcl | |
| PE20080409A1 (es) | Compuestos que modulan en el receptor cb2 | |
| AR080865A1 (es) | Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer. | |
| AR052419A1 (es) | Derivados de bencimidazolil n-sustituidos,inhibidores del protooncogen c-kit | |
| PE20080267A1 (es) | Compuestos triarilicos y sus derivados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |